Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer

被引：14

作者：

Bell, KA ^{[1
]}

Perna, AG ^{[1
]}

Hsu, S ^{[1
]}

机构：

[1] Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2001年 / 45卷 / 05期

关键词：

D O I：

10.1067/mjd.2001.117244

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：790 / 791

页数：2

共 9 条

[1] Xeloda® in the treatment of metastatic breast cancer [J].

Blum, JL .

ONCOLOGY, 1999, 57 :16-20

[2] Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].

Blum, JL ;

Jones, SE ;

Buzdar, AU ;

LoRusso, PM ;

Kuter, I ;

Vogel, C ;

Osterwalder, B ;

Burger, HU ;

Brown, CS ;

Griffin, T .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493

[3] Potential of Xeloda® in colorectal cancer and other solid tumors [J].

Cassidy, J .

ONCOLOGY, 1999, 57 :27-32

[4] Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer [J].

Di Costanzo, F ;

Sdrobolini, A ;

Gasperoni, S .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (02) :101-108

[5]

HUGHES M, 1996, ANN ONCOL S1, V7, P87

[6]

MEROPOL NG, 1996, ANN ONCOL S1, V7, P87

[7]

Moiseyenko V, 1998, ANN ONCOL, V9, P13

[8]

OSHAUGHNESSY J, 1998, P AN M AM SOC CLIN, V17, pA103

[9]

TAGUCHI T, 1996, ANN ONCOL S1, V7, P87

← 1 →